Functional visual field and navigation testing for moderate-to-profound inherited retinal disease
Official title: Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
Run by Ray Therapeutics, Inc. · NCT07502664 · Data updated 2026-11-12
This project will test whether functional visual field and navigation tests can measure real-world vision and mobility in people with moderate-to-profound inherited retinal diseases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Ray Therapeutics, Inc. Industry-sponsored |
| Locations | 1 site (Irvine, California) |
| Status | Recruiting |
| Started | February 19, 2026 |
| Main results expected | February 2027 |
| Study ends | February 2027 |
| Registry record updated | March 31, 2026 |
| Trial ID | NCT07502664 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with bilateral retinitis pigmentosa or other retinal dystrophies affecting peripheral vision, best-corrected visual acuity between 20/200 and hand motions in at least one eye, and the ability to communicate in English or Spanish and complete in-person testing.
✕Probably not a fit
Patients with primarily central-only vision loss outside the stated acuity range, significant cognitive impairment that prevents test completion, current pregnancy, or inability to travel to the study site are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, non-interventional project enrolls people with moderate-to-profound inherited retinal diseases to test and refine visual function endpoints focused on peripheral vision. Participants complete a battery of standardized tasks that measure spatial orientation, mobility, wayfinding, and related functional vision in controlled settings at the Vision Research and Assessment Institute in Irvine, CA. The study emphasizes operational feasibility and measurement properties such as reliability, sensitivity to change, and real-world relevance. Findings will inform selection of endpoints for future therapeutic trials in low-vision populations.
Why it matters
Potential benefit: If successful, the refined endpoints could help clinical trials detect meaningful changes in mobility and peripheral vision and speed development of therapies for low-vision conditions.
How similar studies have gone: Related mobility and navigation outcome measures have been used in prior low-vision research and shown promise, but standardized, regulatory-ready endpoints for peripheral function and wayfinding remain under development.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records * Best-corrected visual acuity between 20/200 to HM in at least one eye. * Reasonably fluent in English or Spanish Exclusion Criteria: * Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing. * Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol * Current pregnancy as reported by patient
Where it's running
-
Vision Research and Assessment Institute
Irvine, California, United States Recruiting
Study contacts
- Study coordinator: Reem Jaber, MS, CGC
- Email: info@vr-ai.com
- Phone: 949-264-3793
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Assessing vision measurement methods for patients with retinal degeneration
This study is testing different ways to measure vision in people with retinal degeneration to see how their eyesight affects daily life and how it changes over time.
-
Disulfiram (Antabuse) for vision in retinal degeneration
This study will test whether taking oral disulfiram (Antabuse) improves vision in adults with retinal degeneration who are also being treated for alcohol use disorder.
-
ASP2020 eye injection safety in Stargardt-type macular dystrophy
A small study will test whether a single ASP2020 eye injection is safe and may help people with Stargardt-type macular dystrophy.
-
Tracking how Stargardt-type macular dystrophy progresses in children and adults
This project will follow children and adults with Stargardt-type macular dystrophies over time to see how their vision and eye findings change.
-
Evaluating a new gene therapy for Stargardt Disease
This study is testing a new gene therapy to see if it can safely help people with Stargardt Disease Type 1 slow down or improve their vision loss.
-
Using stem cells to treat retinal and optic nerve damage
This study is testing if using stem cells from your own bone marrow can help improve vision in people with serious eye damage from conditions like age-related macular degeneration and optic nerve problems.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.